• Services

    Services

    Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens. All the platforms and services are label free with no modification of the original molecules.

    Understand the mode of action of your compound

    Identify and validate drug-target engagement

    Lead compound optimization

    Patient stratification and biomarkers discovery

    Indication prioritization

    Identify biomarkers and clinical pharmacology

    SPR services 

    MoA Screening

  • Technology

    Technology

    Inoviem provides breakthrough protein technologies for each phase of the drug development process.
    One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

    Preclinical

    How to best identify the Mode of Action of your compound

    Read more

    From preclinical to clinical

    Ensure Phase II study and success of your drug candidate in Phase III

    Read more

    Clinical

    Successfully identify the cohort of patients who will respond to your therapy

    Read more

  • Expertise

    Our expertise in translational pharmacology

    Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.

    Translational pharmacology expertise

    Pre-clinical to clinical phases

    Read more

    Our innovative approach

    Biomarkers, patient and therapeutic window

    Read more

    Advantages of approach

    Save time and money

    Read more

    How we work with clients

    Tailored methodologies and technologies 

    Read more

  • Knowledge centre
  • About us

    About us

    Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

    Our mission

    Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

    Read more

    Our team

    • Management team
    • Scientific board
    • Supervisory board & investors

    Read more

  • Contact us

Understand the Mode of Action of your compound with NPOT® technology

Defining your drug candidate’s mechanism of action (MoA) is a critical step in development, regardless of the disease model you’re using. At Inoviem Scientific, we empower you to gain a deeper understanding of your compound’s MoA with our unique expertise and innovative technologies. 

Our team offers two key approaches to help you achieve this

  • Testing efficacy in your disease model: We can test your compound’s efficacy and associated signalling pathway in the same disease model you used for preclinial development 
  • Human-derived evidence: We leverage our extensive biobank of human pathological tissues to analyze your compound’s effectiveness in a patient-relevant context. 

Going beyond the basics: unveiling the interactome

Inoviem goes beyond traditional MoA analysis. We utilize our proprietary NPOT® technology to isolate and identify the entire network of proteins your compound interacts with, including both intended targets (ON targets) and unintended ones (OFF targets). This comprehensive picture, encompassing interactions from the cellular level to organs, empowers you to make informed decisions about your drug development path. 


A patient-centric approach: bridging bench to bedside

The ultimate understanding of your MoA lies in a patient-centric approach. We help you identify, at the molecular level, why patients might respond differently to the same treatment. This approach allows you to develop companion diagnostics that personalize treatment strategies and improve patient outcomes. 

Why choose Inoviem for MoA analysis?

  • Agnostic expertise: We offer extensive experience across various disease areas, including oncology, respiratory, and metabolic disorders. 
  • Exhaustive biobank: Our vast collection of human pathological tissues allows for MoA analysis in a clinically relevant setting.  
  • Clinical MoA expertise: We are the only CRO company delivering clinical MoA data within the human clinical environment, preserving the pathological context and providing invaluable insights at every stage of development. 

Unlock the full potential of your drug candidate with Inoviem's comprehensive MoA

Contact us today to learn more!

Understand the Mode of Action of your compound

Identify and validate drug-target engagement

Lead compound optimization

Patient stratification and biomarkers discovery

Indication priorization

Identify biomarkers and clinical pharmacology

SPR services

Mode of Action Screening

Headquarter
Bioparc 2, 850 boulevard Sébastien Brant,
67400 Illkirch-Graffenstaden

CONTACT US


SERVICES
EXPERTISE

Our expertise in translational pharmacology
Advantages of a translational pharmacology approach
How we work with clients

TECHNOLOGY

Preclinical
From preclinical to clinical
Clinical

RESOURCES
ABOUT US

Our mission
Our team

PRIVACY POLICY
Need Help